Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 254 entries
View as:

Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701

Phase: N/A Priority: Normal
NCT ID: NCT00453440 Org: User:
Start: 03/20/07 End: 08/10/07 Due: 08/10/08

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Phase: N/A Priority: Normal
NCT ID: NCT06694805 Org: User:
Start: 12/02/24 End: 12/08/27 Due: 12/08/28

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

Phase: N/A Priority: Normal
NCT ID: NCT06741397 Org: User:
Start: 12/20/24 End: 01/10/29 Due: 01/10/30

Relative Bioavailability Study of GSK1265744 Formulations

Phase: N/A Priority: Normal
NCT ID: NCT01648257 Org: User:
Start: 08/31/12 End: 11/30/12 Due: 11/30/13

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

Phase: N/A Priority: Normal
NCT ID: NCT00040664 Org: User:
Start: 07/31/02 End: 10/31/08 Due: 10/31/09

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT06786520 Org: User:
Start: 01/17/25 End: 11/08/27 Due: 11/08/28

Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02159131 Org: User:
Start: 08/31/14 End: 12/31/14 Due: 12/31/15

Study of Combined Oral Contraceptive Effects in Female Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02157467 Org: User:
Start: 06/02/14 End: 08/25/14 Due: 08/25/15

HIV Treatment and CVD Events

Phase: N/A Priority: Normal
NCT ID: NCT01054638 Org: User:
Start: 03/31/09 End: 12/31/10 Due: 12/31/11

A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India

Phase: N/A Priority: Normal
NCT ID: NCT00992654 Org: User:
Start: - End: - Due: -

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

Phase: N/A Priority: Normal
NCT ID: NCT01345630 Org: User:
Start: 09/30/11 End: 01/31/14 Due: 01/31/15

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04128293 Org: User:
Start: 10/08/19 End: 11/15/19 Due: 11/15/20

GSK1349572 Hepatic Impairment Study

Phase: N/A Priority: Normal
NCT ID: NCT01231529 Org: User:
Start: 11/19/10 End: 06/04/11 Due: 06/04/12

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02120352 Org: User:
Start: 04/28/14 End: 04/20/23 Due: 04/20/24

Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent

Phase: N/A Priority: Normal
NCT ID: NCT03984838 Org: User:
Start: 06/17/19 End: 08/13/19 Due: 08/13/20

Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

Phase: N/A Priority: Normal
NCT ID: NCT03984812 Org: User:
Start: 06/17/19 End: 03/23/20 Due: 03/23/21

A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00296504 Org: User:
Start: 11/30/01 End: 10/31/10 Due: 10/31/11

DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)

Phase: N/A Priority: Normal
NCT ID: NCT02063360 Org: User:
Start: 02/01/14 End: 05/13/14 Due: 05/13/15

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

Phase: N/A Priority: Normal
NCT ID: NCT04542070 Org: User:
Start: 11/09/20 End: 04/17/23 Due: 04/17/24

A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

Phase: N/A Priority: Normal
NCT ID: NCT05776108 Org: User:
Start: 03/23/23 End: 06/08/23 Due: 06/08/24

Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

Phase: N/A Priority: Normal
NCT ID: NCT02893488 Org: User:
Start: 09/01/16 End: 11/25/16 Due: 11/25/17

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

Phase: N/A Priority: Normal
NCT ID: NCT01209065 Org: User:
Start: 09/30/10 End: 11/30/10 Due: 11/30/11

A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04857892 Org: User:
Start: 04/21/21 End: 09/10/21 Due: 09/10/22

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT00782301 Org: User:
Start: 03/31/09 End: 02/28/10 Due: 02/28/11

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01273103 Org: User:
Start: 01/31/11 End: 02/28/11 Due: 02/28/12